Comparative Study of Metformin Versus Myo-Inositol with D-chiro-Inositol on the Clinical, Hormonal and Metabolic Profiles in infertile women with PCOS: An Open-Label Randomized Trial - NIL

Start Date15 Apr 2025

Sponsor / Collaborator

Jawaharlal Institute of Post Graduate Medical Education & Re

NCT06575868

/ RecruitingNot ApplicableIIT

Continuous Glucose Monitoring in Myo-inositol Supplemented Obese Pregnant Individuals: a Feasibility Pilot Randomized Control Trial

Myoinositol is an insulin-like compound that is present in both plant and animal cells. Humans synthesize it naturally, but it is also obtained in our diet. It works through an intracellular signaling pathway to increase insulin sensitivity. Myoinositol has been used as an over-the-counter (OTC) supplement in the management of polycystic ovarian syndrome due to this effect. Myoinositol has also been shown to improve glycemic profiles in pregnant euglycemic women and well as improve insulin sensitivity in pregnant patients with gestational diabetes mellitus (GDM).
This is a double blind RCT offering myo-inositol or placebo to those who are eligible and enrolled.

Start Date01 Mar 2025

Sponsor / Collaborator

Tufts Medical Center, Inc.

ChiCTR2500096966

/ SuspendedPhase 4IIT

Effect of inositol on metabolism-related indexes in lean patients with polycystic ovary syndrome

Start Date15 Feb 2025

Sponsor / Collaborator

The First Affiliated Hospital of Xiamen University

100 Clinical Results associated with Inositol

100 Translational Medicine associated with Inositol

100 Patents (Medical) associated with Inositol

20,582

Literatures (Medical) associated with Inositol

31 Dec 2025·Gynecological Endocrinology

Improved insulin sensitivity and reproductive profile in overweight/obese PCOS patients undergoing integrative treatment with carnitines, L-arginine, L-cysteine and myo-inositol

Article

Author: Foschi, Martina ; Szeliga, Anna ; Semprini, Elisa ; Spelta, Eleonora ; Kostrzak, Anna ; Genazzani, Alessandro D. ; Rusce, Maria Laura ; Aio, Claudia ; Battipaglia, Christian ; Meczekalski, Blazej

OBJECTIVETo evaluate the effects of a combination of carnitines, L-arginine, L-cysteine and myo-inositol on metabolic and reproductive parameters in PCOS overweight/obese patients.METHODSThis was a retrospective study analyzing information of a group of PCOS (n = 25) overweight/obesity patients, not requiring hormonal treatment, selected from the database of the ambulatory clinic of the Gynecological Endocrinology Center at the University of Modena and Reggio Emilia, Modena, Italy. The hormonal profile, routine exams and insulin and C-peptide response to oral glucose tolerance test (OGTT) were evaluated before and after 12 weeks of a daily oral complementary treatment with L-carnitine (500 mg), acetyl-L-carnitine (250 mg), L-arginine (500 mg), L-cysteine (100 mg) and myo-inositol (1 gr). The hepatic insulin extraction index was also calculated.RESULTSThe mix of complementary substances significantly improved metabolic parameters, homeostatic model assessment for insulin resistance index values and gonadotropin plasma levels. Glucose, C-peptide and insulin response to OGTT was significantly reduced as well as the hepatic insulin extraction index.CONCLUSIONThe administration of a combination of carnitines, L-arginine, L-cysteine and myoinositol improved gonadotropin plasma levels and insulin sensitivity in overweight/obese PCOS patients and restored hepatic clearance of insulin as demonstrated by the decreased hepatic insulin extraction index.

01 Aug 2025·Biomaterials

Bio-orthogonal-labeled exosomes reveals specific distribution in vivo and provides potential application in ARDS therapy

Article

Author: Yang, Song ; Zhang, Chunling ; Sun, Na ; Song, Junna ; Wang, Rui ; Yin, Xiaona ; Zhu, Haomiao ; Zhao, Wei ; Liu, Huadong ; Wu, Xiao ; Wang, Kun ; Jin, Hongzhen ; Yu, Fan ; Liu, Yonghui

Exosomes derived from specific cells may be useful for targeted drug delivery, but tracking them in vivo is essential for their clinical application. However, their small size and complex structure challenge the development of exosome-tracking techniques, and traditional labeling methods are limited by weak affinity and potential toxicity. To address these issues, here we developed a novel bio-orthogonal labeling strategy based on phosphatidylinositol derivatives to fluorescently label exosomes from various human and mouse cell types. The different cell-derived exosomes revealed organ-specific distribution patterns and a favorable safety profile. Notably, 4T1 cell-derived exosomes specifically targeted the lungs. When used as drug carriers loaded with anti-inflammatory resveratrol, these exosomes showed significant therapeutic efficacy in mice with acute respiratory distress syndrome (ARDS), effectively reducing inflammatory responses, mitigating pulmonary fibrosis, and restoring lung tissue morphology and function. Our findings provide a novel exosome labeling strategy and an invaluable tool for their in vivo tracking and targeting screening, while exosomes that specifically target the lungs offer a potential therapeutic strategy for organ-specific diseases such as ARDS.

01 Jun 2025·One Health

Subtle genomic differences in Klebsiella pneumoniae sensu stricto isolates indicate host adaptation

Article

Author: Ronholm, Jennifer ; O'Brien, Bridget ; Dufour, Simon ; Fanning, Séamus ; Jung, Dongyun ; Yushchenko, Alla ; Nguyen, Ngoc Sang ; Semret, Makeda ; Suh, Jinha ; Cai, Zhangbin

Klebsiella pneumoniae sensu stricto (KpI) is an opportunistic pathogen capable of residing as a commensal in both human and bovine intestinal tracts and can cause serious systemic infections in humans and severe clinical mastitis in dairy cattle. It is unclear what role zoonotic and anthroponotic transmission play in the dissemination of KpI. In this study, we use a comparative genomic approach to identify differences between KpI associated with disease in humans and cattle and aimed to identify any potential genetic barriers limiting transmission of KpI between these two hosts. A total of 128 KpI strains (bovine n = 65; human n = 63) were whole genome sequenced and human and bovine strains were compared based on phylogenomics, the pangenome, mobile genetic elements, and differential gene abundance. No obvious phylogenomic differentiation was observed between isolates from these hosts. However, subtle genetic differences exist between bovine and human KpI which likely reflect environmental adaptation to different host niches, including a higher representation of gene clusters encoding ferric citrate uptake transporters, as well as histidine, arginine, and lactose utilization pathways in bovine isolates. These gene clusters may be positively selected due to the unique metabolic environment of the mammary gland, where lactose, citrate-bound iron, and amino acids like histidine and arginine provide growth advantages for KpI during mastitis. Overall, our study identified no obvious genetic barriers to zoonotic transmission of KpI within the dairy environment and provides insight into the development of host-specific therapeutic options for KpI infections in humans and bovine.

News (Medical) associated with Inositol

17 Oct 2024

·www.prnewswire.com

Nikon Small World Competition Celebrates 50 Years with Groundbreaking Image of Brain Tumor Cells

Celebrating its golden anniversary, Nikon Small World honors a stunning photo of brain tumor cell structures, advancing our understanding of neurodegenerative diseases. MELVILLE, N.Y., Oct. 17, 2024 /PRNewswire/ -- Nikon Instruments Inc. today announced the winners of the 50th annual Nikon Small World Photomicrography Competition, celebrating five decades of excellence in microscopy and digital imaging. This year's first place prize was awarded to Dr. Bruno Cisterna, with assistance from Dr. Eric Vitriol of Augusta University, for his groundbreaking image of differentiated mouse brain tumor cells, highlighting the actin cytoskeleton, microtubules, and nuclei. This image reveals how disruptions in the cell's cytoskeleton – the structural framework and "highways" known as microtubules – can lead to diseases like Alzheimer's and ALS. Continue Reading Differentiated mouse brain tumor cells (actin, microtubules, and nuclei) Dr. Cisterna's research revealed that profilin 1 (PFN1), a protein crucial for building the cell's structure, plays a key role in maintaining the microtubule highways essential for cellular transport. When PFN1 or related processes are disrupted, these highways can malfunction, leading to cellular damage similar to what is observed in neurodegenerative diseases. "One of the main problems with neurodegenerative diseases is that we don't fully understand what causes them," said Dr. Cisterna. "To develop effective treatments, we need to figure out the basics first. Our research is crucial for uncovering this knowledge and ultimately finding a cure. Differentiated cells could be used to study how mutations or toxic proteins that cause Alzheimer's or ALS alter neuronal morphology, as well as to screen potential drugs or gene therapies aimed at protecting neurons or restoring their function." His patience and determination were crucial in capturing his image. "I spent about three months perfecting the staining process to ensure clear visibility of the cells. After allowing five days for the cells to differentiate, I had to find the right field of view where the differentiated and non-differentiated cells interacted. This took about three hours of precise observation under the microscope to capture the right moment, involving many attempts and countless hours of work to get it just right." The hard work behind this discovery underscores its significance, bringing researchers closer to answers that could potentially transform millions of lives. "After three years of research, we finally published our findings four months ago in the Journal of Cell Biology, and there's still more work to be done," said Dr. Cisterna. "I'm deeply passionate about scientific imaging; I've been following the Nikon Small World contest for about 15 years. It's an incredible contest that highlights the beauty of photomicrography but also inspires continued exploration and innovation in the field." Eric Flem, Senior Manager, CRM and Communications at Nikon Instruments, shares a similar perspective on the competition. "At 50 years, Nikon Small World is more than just an imaging competition – it's become a gallery that pays tribute to the extraordinary individuals who make it possible. They are the driving force behind this event, masterfully blending science and art to reveal the wonders of the microscopic world and what we can learn from it to the public." He went on to add, "Sometimes, we overlook the tiny details of the world around us. Nikon Small World serves as a reminder to pause, appreciate the power and beauty of the little things, and to cultivate a deeper curiosity to explore and question." Second place was awarded to Dr. Marcel Clemens for his image of an electrical arc between a pin and a wire, produced by applying a potential difference of 10,000 volts. Third place was awarded to Chris Romaine for his image of a cannabis plant leaf. The bulbous structures are trichomes, or hair-like plant appendages, and the bubbles inside are cannabinoid vesicles, fluid-filled, blister-like structures. In total, Nikon Small World recognized 87 photos out of thousands of entries from scientists and artists across the globe. The 2024 judging panel included: Adrian Coakley, Director of Photography at National Geographic Books Michelle S. Itano, Ph.D., Assistant Professor of Cell Biology and Physiology and Director of the Neuroscience Microscopy Core at the University of North Carolina at Chapel Hill Emily Petersen, Photography Managing Editor at Science Magazine Clare Waterman, Ph.D., Cell Biologist and Member of the National Academy of Sciences Jennifer C. Waters, Ph.D., Director of the Core for Imaging Technology & Education at Harvard Medical School Samantha Yammine, Ph.D., Neuroscientist and Science Communicator For additional information, please visit , or follow the conversation on Facebook, Twitter @NikonSmallWorld and Instagram @NikonInstruments. NIKON SMALL WORLD WINNERS 1st Place Dr. Bruno Cisterna & Dr. Eric Vitriol Medical College of Georgia at Augusta University Department of Neuroscience & Regenerative Medicine Augusta, Georgia, USA Differentiated mouse brain tumor cells (actin, microtubules, and nuclei) Super-Resolution 100X (Objective Lens Magnification) 2nd Place Dr. Marcel Clemens Verona, Veneto, Italy Electrical arc between a pin and a wire Image stacking for the pin and wire combined with long exposure for the electrical arcs 10X (Objective Lens Magnification) 3rd Place Chris Romaine Kandid Kush Port Townsend, Washington, USA Leaf of a cannabis plant. The bulbous glands are trichomes. The bubbles inside are cannabinoid vesicles. Image Stacking 20X (Objective Lens Magnification) 4th Place Dr. Amy Engevik Medical University of South Carolina Department of Regenerative Medicine & Cell Biology Charleston, South Carolina, USA Section of a small intestine of a mouse Fluorescence 10X (Objective Lens Magnification) 5th Place Thomas Barlow & Connor Gibbons Columbia University Department of Neurobiology and Behavior New York, New York, USA Cluster of octopus (Octopus hummelincki) eggs Darkfield, Stereomicroscopy, Focus Stacking 3X (Objective Lens Magnification) 6th Place Henri Koskinen Helsinki University Helsinki, Uudenmaan lääni, Finland Slime mold (Cribraria cancellata) Image Stacking, Polarized Light, Reflected Light 10X (Objective Lens Magnification) 7th Place Gerhard Vlcek Maria Enzersdorf, Austria Cross section of European beach grass (Ammophila arenaria) leaf Brightfield, Image Stacking 10X (Objective Lens Magnification) 8th Place Stephanie Huang Victoria University of Wellington School of Biological Sciences; School of Psychology Wellington, New Zealand A neuron densely covered in dendritic spines from the striatum of an adult rat brain Confocal, Deconvolution, Image Stacking 60X (Objective Lens Magnification) 9th Place John-Oliver Dum Medienbunker Produktion Bendorf, Rheinland Pfalz, Germany Pollen in a garden spider (Araneus) web Image Stacking 20X (Objective Lens Magnification) 10th Place Jan Martinek Charles University Department of Experimental Plant Biology Prague, Czech Republic Spores of black truffle (Tuber melanosporum) Confocal 63X (Objective Lens Magnification) 11th Place Dr. Ferenc Halmos Bánd, Veszprém, Hungary Slime mold on a rotten twig with water droplets Image Stacking 0.7X - 4.5X (Objective Lens Magnification) 12th Place Daniel Knop Oberzent-Airlenbach, Hessen, Germany Wing scales of a butterfly (Papilio ulysses) on a medical syringe needle Image Stacking 20X (Objective Lens Magnification) 13th Place Paweł Błachowicz Bedlno, Świętokrzyskie, Poland Eyes of green crab spider (Diaea dorsata) Image Stacking, Reflected Light 20X (Objective Lens Magnification) 14th Place Marek Miś Marek Miś Photography Suwalki, Podlaskie, Poland Recrystallized mixture of hydroquinone and myoinositol Polarized Light 10X (Objective Lens Magnification) 15th Place Sébastien Malo Saint Lys, Haute-Garonne, France Isolated scales on Madagascan sunset moth wing (Chrysiridia ripheus) Darkfield, Image Stacking, Reflected Light 40X (Objective Lens Magnification) 16th Place Marek Miś Marek Miś Photography Suwalki, Podlaskie, Poland Two water fleas (Daphnia sp.) with embryos (left) and eggs (right) Darkfield, Polarized Light 10X (Objective Lens Magnification) 17th Place Dr. Frantisek Bednar Svosov, Zilinsky, Slovak Republic Stonewort algae (Chara virgata) reproductive organs - oogonia (female organs) and antheridia (male organs) Darkfield 4X (Objective Lens Magnification) 18th Place Alison Pollack San Anselmo, California, USA An insect egg parasitized by a wasp Image Stacking, Reflected Light 10X (Objective Lens Magnification) 19th Place Alison Pollack San Anselmo, California, USA Seed of a Silene plant Image Stacking, Reflected Light 10X (Objective Lens Magnification) 20th Place Dr. Bruno Cisterna & Dr. Eric Vitriol Medical College of Georgia at Augusta University Department of Neuroscience & Regenerative Medicine Augusta, Georgia, USA Early stage of mouse neuroblastoma cell differentiation (actin, microtubules, and mitochondria) Super-Resolution 100X (Objective Lens Magnification) HM Christopher Algar Hounslow, Middlesex, United Kingdom Brine shrimp Darkfield, Image Stacking, Polarized Light 4X (Objective Lens Magnification) HM Dr. Kseniia Bondarenko University of Edinburgh Institute for Immunology and Infection Research Edinburgh, MidLothian, United Kingdom Acute-stage parasites of Toxoplasma gondii in a human skin cell Expansion Microscopy, Confocal, Deconvolution 100X (Objective Lens Magnification) HM Dr. Anja de Lange University of Cape Town Neuroscience Institute & Department of Human Biology Cape Town, Western Cape, South Africa Astrocytes surrounding a blood vessel in a thin slice of human brain Confocal 40X (Objective Lens Magnification) HM Dr. Amy Engevik Medical University of South Carolina Department of Regenerative Medicine & Cell Biology Charleston, South Carolina, USA Intestinal villi Fluorescence 20X (Objective Lens Magnification) HM Daniel Evrard Aywaille, Liege, Belgium Vinyl player needle on scratched vinyl disk Image Stacking, Polarized Light 20X (Objective Lens Magnification) HM Randy Fullbright Fullbright Studio Vernal, Utah, USA Agatized dinosaur bone Image Stacking 10X (Objective Lens Magnification) HM Dr. David Maitland St. Andrews, Fife, United Kingdom Transverse section of rachis (stem) of bracken fern (Pteridium aquilinum) Differential Interference Contrast (DIC) 5X (Objective Lens Magnification) HM Angus Rae Australian National University Centre for Advanced Microscopy MacGregor, Australian Capital Territory, Australia Autofluorescence in the face of a little two-spotted ladybird (Diomus notescens) Fluorescence lifetime imaging microscopy (FLIM) 20X (Objective Lens Magnification) HM Dr. Igor Robert Siwanowicz Howard Hughes Medical Institute (HHMI), Janelia Research Campus Ashburn, Virginia, USA Antenna of a mole crab Confocal 10X (Objective Lens Magnification) HM Jochen Stern Mannheim, Baden-Wuerttemberg, Germany Golden bug eggs on a sage leaf Image Stacking 20X (Objective Lens Magnification) HM Dr. Bruce Douglas Taubert Glendale, Arizona, USA Ocelli between the compound eyes of a yellow jacket Reflected Light 10X (Objective Lens Magnification) HM Kevin Terretaz CRBM-CNRS Montpellier, Hérault, France Mosquito cells in culture with fluorescent markers for DNA and microtubules Confocal 63X (Objective Lens Magnification) IoD Dr. Sherif Abdallah Ahmed Tanta University, Faculty of Science Department of Zoology Tanta, Egypt, Arab Republic Anterior section of palm weevil Image Stacking 4X (Objective Lens Magnification) IoD Anne Patricia Algar Hounslow, Middlesex, United Kingdom Mosquito larva Darkfield, Image Stacking, Polarized Light 4X (Objective Lens Magnification) IoD Dr. Florian Alonso University of Bordeaux BioTis-INSERM U1026 Pessac, Gironde, France Mouse aortic endothelium stained for beta-catenin (green), laminin (purple), smooth muscle actin (red), and Hoechst (cyan) Confocal 63X (Objective Lens Magnification) IoD Didier Barbet Club Français de Microscopie Bailly, France Fracture surface of mica (mineral) Differential Interference Contrast (DIC) 10X (Objective Lens Magnification) IoD Timothy Boomer WildMacro.com Vacaville, California, USA Slime mold (Prototrichia metallica) Image Stacking 10X (Objective Lens Magnification) IoD Zhang Chao National Astronomical Observatories, Chinese Academy of Sciences Beijing, China Beach sand Reflected Light 10X (Objective Lens Magnification) IoD Joshua Coogler Dallas, North Carolina, USA Moss sporophyte with spores (green) Image Stacking 10X (Objective Lens Magnification) IoD Nikky Corthout & Miranda Dyson VIB (Flanders Institute of Biotechnology) Center for Brain and Disease Research Leuven, Vlaams-Brabant, Belgium Fruit fly (Drosophila) brain vasculature Confocal, Fluorescence, Image Stacking, Super-Resolution 25X (Objective Lens Magnification) IoD Nadia Efimova Amicus Therapeutics Philadelphia, Pennsylvania, USA Dandelion pappus Confocal, Fluorescence 20X (Objective Lens Magnification) IoD Dr. Laurent Formery & Dr. Nathaniel Clarke Stanford University Department of Molecular and Cell Biology Pacific Grove, California, USA Nervous system of a young sea star Confocal, Fluorescence 10X (Objective Lens Magnification) IoD Karl Gaff Dublin, Ireland Larva of a midge fly (Chironomidae) Darkfield, Image Stacking, Polarized Light 20X (Objective Lens Magnification) IoD Dr. Nick Gatford University of Oxford Nuffield Department of Clinical Neurosciences (NDCN) Oxford, Oxfordshire, United Kingdom A network of dopaminergic neurons generated from human stem cells Super-Resolution 63X (Objective Lens Magnification) IoD Dr. Saikat Ghosh National Institutes of Health NICHD Bethesda, Maryland, USA Human neurons Confocal 40X (Objective Lens Magnification) IoD Gerd A. Günther Düsseldorf, Germany Cross section of a beach grass (Ammophila arenaria) leaf Fluorescence 20X (Objective Lens Magnification) IoD Anna-Mari Elisabeth Haapanen-Saaristo University of Turku Turku Bioscience Centre / Cell Imaging & Cytometry Core and Zebrafish Core RAISIO, Varsinais-Suomi, Finland Nutrient storage cells in a tardigrade Confocal 25X (Objective Lens Magnification) IoD Dr. Martin Hein Lions Eye Institute Physiology and Pharmacology laboratory Nedlands, Western Australia, Australia Abnormal blood vessel formation in a human retina with severe diabetic retinopathy Confocal 20X (Objective Lens Magnification) IoD Wen Jie Ji Yin Works The Bureau of Microworld Exploration Beijing, China Integrated circuit chip Reflected Light 10X (Objective Lens Magnification) IoD Ted Kinsman Rochester Institute of Technology Photosciences Department Rochester, New York, USA A common house cat claw Polarized Light 10X (Objective Lens Magnification) IoD Daniel Knop Oberzent-Airlenbach, Hessen, Germany Opening of a hibiscus flower (Hibiscus moscheutos) exposing the pollen in four stages, each ten minutes apart Image Stacking 20X (Objective Lens Magnification) IoD Daniel Knop Oberzent-Airlenbach, Hessen, Germany Dorsal part of cuckoo wasp (Hedychrum gerstaeckeri) abdomen Image Stacking 20X (Objective Lens Magnification) IoD Dr. Håkan Kvarnström Bromma, Sweden Peacock plume feather Epi-Illumination, Image Stacking 4X (Objective Lens Magnification) IoD Dr. Ewa Langner Washington University in St Louis Department of Medicine - Renal Division, Mahjoub Lab St Louis, Missouri, USA Mouse embryonic kidney showing interstitial fibroblasts (yellow), tubular epithelium (cyan), and nuclei (magenta) Confocal, Fluorescence, Image Stacking 40X (Objective Lens Magnification) IoD Dr. Amir Maqbool Lovely Professional University Department of Zoology Srinagar, Jammu and Kashmir, India Small fly killed by "zombie fly" fungus (Entomophthora muscae) Image Stacking 2X (Objective Lens Magnification) IoD Dr. Robert Markus University of Nottingham School of Life Sciences, Super Resolution Microscopy Nottingham, Nottinghamshire, United Kingdom Dandelion (Traxacum officinale) cross section showing curved stigma with pollen Confocal 10X (Objective Lens Magnification) IoD Dr. Robert Markus, Dr. Zeeshan Mohammad, Dr. Sarah Pashley & Dr. Rita Tewari University of Nottingham School of Life Sciences, Super Resolution Microscopy Nottingham, Nottinghamshire, United Kingdom Malaria parasites and mouse blood cells - tubulin (green), all proteins (purple), DNA (red) Confocal 63X (Objective Lens Magnification) IoD Jan Martinek Charles University Department of Experimental Plant Biology Prague, Czech Republic Spores of a black Bagnoli truffle (Tuber mesentericum) Confocal 63X (Objective Lens Magnification) IoD Dr. Guillermo Moya Johns Hopkins University Department of Biology Baltimore, Maryland, USA Neuronal axons connecting to the muscles of the iris and the cornea Confocal, Fluorescence 10X (Objective Lens Magnification) IoD Jacek Myslowski Wloclawek, Kujawko-Pomorskie, Poland Water mite (Arrenurus) Fluorescence, Image Stacking 6.3X (Objective Lens Magnification) IoD Aryah Nagarajan Falmouth University Institute of Photography Penryn, Cornwall, United Kingdom Spores releasing from the sori of a Polypody fern (Polypodium vulgare) Reflected Light, Transmitted Light, Focus Stacking 10X (Objective Lens Magnification) IoD Thomas Neumann Tübingen, Baden-Württemberg, Germany Ink dot on Japanese washi paper Brightfield, Image Stacking 20X (Objective Lens Magnification) IoD Satu Paavonsalo & Dr. Sinem Karaman University of Helsinki Individualized Drug Therapy Research Program, Faculty of Medicine, Helsinki, Finland Helsinki, Finland Blood vessels (color gradient) and endothelial cell nuclei (white) in the intestinal villi of a mouse Confocal 10X (Objective Lens Magnification) IoD Uwe Lange Hannover, Niedersachsen, Germany Pollen on the compound eyes of a fly Image Stacking 60X (Objective Lens Magnification) IoD Dr. Marko Pende MDI Biological Laboratory Murawala Lab Bar Harbor, Maine, USA Ladybug (Coccinellidae) on a clover (Trifolium repens) Confocal, Fluorescence, Image Stacking 4X (Objective Lens Magnification) IoD Dr. Felice Placenti FP Nature and Landscape Photography Siracusa, Sicilia, Italy Potato tuber sprout Image Stacking, Reflected Light 1X (Objective Lens Magnification) IoD Alison Pollack San Anselmo, California, USA Slime mold (Lamproderma arcyrioides) Image Stacking, Reflected Light 10X (Objective Lens Magnification) IoD Dr. Gonzalo Quiroga Artigas CRBM-CNRS Montpellier, Herault, France Tardigrade (Hypsibius exemplaris) Confocal 40X (Objective Lens Magnification) IoD Chris Romaine Kandid Kush Port Townsend, Washington, USA Bract (part of the plants reproductive structures) of a cannabis plant. The bulbous glands are trichomes. Image Stacking 20X (Objective Lens Magnification) IoD Dr. Adolfo Ruiz De Segovia PARTICULAR Madrid, Spain Plant root Fiber Optic 2X (Objective Lens Magnification) IoD Yurim Seo, Dr. Mark Looney & Dr. Simon Cleary University of California, San Francisco Pulmonary, Critical Care, Allergy and Sleep Medicine San Francisco, California, USA Lymphatic vasculature (cyan) and vessels (red) of a mouse lung Confocal 4X (Objective Lens Magnification) IoD Dr. Leo Serra University of Cambridge Sainsbury Laboratory Cambridge, Cambridgeshire, United Kingdom Leaves arising from thale cress (Arabidopsis thaliana) meristem Confocal 20X (Objective Lens Magnification) IoD Dr. Igor Robert Siwanowicz Howard Hughes Medical Institute (HHMI), Janelia Research Campus Ashburn, Virginia, USA Aster anther cross section with pollen grains (green) Confocal 40X (Objective Lens Magnification) IoD Dr. Igor Robert Siwanowicz Howard Hughes Medical Institute (HHMI), Janelia Research Campus Ashburn, Virginia, USA Floret of a common chicory with pollen grains (spiky balls) Confocal 40x (Objective Lens Magnification) IoD Luna Šošo Zdravković, Michael Surala & Christian Madry Charité Universitätsmedizin Berlin Institute of Neurophysiology Berlin, Germany Pyramidal neuron in mouse hippocampus Confocal, Fluorescence, Image Stacking 30X (Objective Lens Magnification) IoD Dr. Bruce Douglas Taubert Glendale, Arizona, USA Mid-tibial tuft on a male orchid bee, used to attract mates Reflected Light 10X (Objective Lens Magnification) IoD Maxime Teixeira Laval University Department of Molecular Medicine Québec, Canada Cultured monkey kidney cells labeled for tubulin (blue) and actin (orange) showing pathological accumulation of alpha-syn aggregates (red) Confocal, Deconvolution, Image Stacking, Super-Resolution 100X (Objective Lens Magnification) IoD Dr. Theo Theune Oost-Souburg, Zeeland, Netherlands Abdominal skin of a tick that engorged with blood Image Stacking 50X (Objective Lens Magnification) IoD Dr. Grigorii Timin & Dr. Michel Milinkovitch University of Geneva Department of Genetics and Evolution Geneva, Switzerland Skin scales of a snake embryo stained with Fast Green dye Confocal 63X (Objective Lens Magnification) IoD Steven A. Valley Oregon Department of Agriculture (ODA) Entomology Lab Albany, Oregon, USA Immature male damselfly (Calopteryx aequabilis) Image Stacking, Reflected Light 5X (Objective Lens Magnification) IoD Dr. Bruno Vellutini Max Planck Institute of Molecular Cell Biology and Genetics Dresden, Saxony, Germany Gene expression patterns in a drain fly embryo (Clogmia albipunctata) with an open eggshell Confocal 20X (Objective Lens Magnification) IoD Susannah Waxman & Dr. Ian Sigal University of Pittsburgh Department of Ophthalmology Pittsburgh, Pennsylvania, USA Optic nerve head collagen of a pig Image Stacking, Multiphoton 25X (Objective Lens Magnification) IoD Shao Yang Beijing Miteyide Culture Co., Ltd. Beijing, China Fiber of nylon stockings Polarized Light 5X (Objective Lens Magnification) IoD Chew Yen Fook Woodend, Waimakiriri, New Zealand Graffiti from Berlin Wall stone section Image Stacking, Top Illumination 10X (Objective Lens Magnification) IoD Chew Yen Fook Woodend, Waimakiriri, New Zealand Water mite (Hydrachna sp.) Darkfield, Image Stacking, Polarized Light 20X (Objective Lens Magnification) IoD Elkhan Yusifov & Dr. Martina Schaettin University of Zurich Department of Molecular Life Sciences Zurich, Switzerland Developing nervous system in the eye of a 7-day-old chick embryo Stereomicroscopy 10X (Objective Lens Magnification) IoD Ou Zhilei Guangdong Radio and Television Guangzhou, Guagndong, China Stamens of flowers (Anemone cathayensis Kitag. ex Ziman & Kadota) Image Stacking 10X (Objective Lens Magnification) About Nikon Small World Photomicrography Competition The Nikon Small World Competition is open to anyone with an interest in photography or video. Participants may upload digital images and videos directly at . For additional information, contact Nikon Small World, Nikon Instruments Inc., 1300 Walt Whitman Road, Melville, NY 11747, USA, or phone (631) 547-8569. Entry forms for Nikon's 2025 Small World and Small World in Motion Competitions are available at . About Nikon Instruments Inc. Nikon Instruments Inc. is the US microscopy arm of Nikon Healthcare, a world leader in the development and manufacturing of optical, digital imaging technology and software for biomedical applications. For more information, please visit or contact us at 1-800-52-NIKON. SOURCE Nikon Instruments Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

17 Jul 2024

·www.globenewswire.com

Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy

– 43% of Participants Showed Improvement on the UMSARS Activities of Daily Living Scale – – 29% of Participants had Stable or Improved Neurological Symptoms – – Objective Biomarkers Demonstrated Improvement Consistent with Clinical Findings – – ATH434 was Well-Tolerated with No Safety Signals Detected – MELBOURNE, Australia and SAN FRANCISCO, July 17, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced positive interim data from the ATH434-202 open-label Phase 2 clinical trial in patients with multiple system atrophy (MSA). ATH434 has been shown preclinically to reduce α-synuclein pathology and preserve neuronal function by restoring normal iron balance in the brain. The interim analysis included clinical and biomarker data on 7 participants treated with ATH434 for 6 months and neuroimaging data on 3 participants who were treated for 12 months. After 6 months of treatment, 43% of participants showed improvement on the UMSARS1, indicating reduced disability on activities of daily living. Over the same period, 29% of participants had stable or improved neurological symptoms (clinical responders) as assessed by both the treating physician and the patient. Importantly, the clinical responders on average had reduced accumulation of iron on MRI in the substantia nigra, putamen and globus pallidus and stable levels of NFL, a marker of axonal injury, when compared to participants who declined. “I am very encouraged by these positive interim data in advanced MSA patients,” said David Stamler, M.D., Chief Executive Officer of Alterity. “As MSA is a rapidly progressive and unremitting disease, we expected to see decline in all participants. Instead, we saw favorable clinical and biomarker outcomes in some patients suggesting that ATH434 has the potential to modify the course of this devastating condition. We were also very pleased to see that the clinical responders had biomarker evidence of stable disease as this provides an objective indication of potential efficacy.” Dr. Stamler, continued, “In the ATH434-202 trial, the participants who stabilized or improved with ATH434 treatment had less advanced disease than those who progressed. This is noteworthy as we have enrolled earlier stage MSA patients in our randomized, double-blind clinical trial ATH434-201. Although the number of patients studied thus far is small, the new data reinforces that we have taken the right approach in our randomized trial and increases my overall confidence in the ATH434 development program.” Daniel Classen, M.D., M.S., Professor of Neurology at Vanderbilt University Medical Center and principal investigator for the ATH434-202 Phase 2 study, commented “I am gratified to see that the work we have done over the last several years is bearing fruit as we enhance our understanding of MSA. This has led to improved patient selection and optimized biomarker endpoints in the Alterity Phase 2 trials. The clinical observations in the ATH434-202 study are supported by the objective biomarkers of brain volume, brain iron, and NfL. These early data increase our confidence that we have chosen the right biomarker and clinical endpoints to evaluate the potential effect of ATH434 in individuals with MSA. I am grateful to the study participants and their family members for their contributions to the study.” ATH434-202 Interim Results A total of 10 participants have been enrolled in the trial. The interim data reported today is from the 7 patients who have completed six months of treatment with ATH434, 3 of whom have also completed 12 months of treatment. Only neuroimaging data are available from month 12. The participants in the trial were diagnosed with MSA using a multimodal approach (clinical, neuroimaging, fluid biomarkers) and treated with oral ATH434 75 mg twice daily. Clinical, biomarker and safety assessments were conducted during the study. While the data are preliminary, the Company sees a positive trend with the current participant patient outcomes. Clinical Assessments at Month 6 Unified MSA Rating Scale Part I, historical review (UMSARS) 43% (3/7) of participants had lower scores (improvement) on the UMSARS that assesses activities of daily living affected in MSA, such as speech, swallowing, walking and urinary/bowel function.In the trial, mean (SD) UMSARS scores (N=7) increased from baseline to 6 months by 1.7 (5.1) points. These study data compare favorably to historical data in a similar MSA population that demonstrated an increase of 3.9 (4.6) points over 6 months.2 Global Impression of Change 29% (2/7) of participants stabilized or improved on the Clinical Global Impression of Change (CGIC) scale, which asks the investigator to evaluate overall neurological symptoms as compared to immediately before starting therapy.29% (2/7) of participants also stabilized or improved on the Patient Global Impression of Change (PGIC) scale which asks the patient to evaluate their overall neurological symptoms as compared to immediately before starting therapy. Safety In general, ATH434 was well tolerated by study participants and most adverse events were mild to moderate in severity.No serious adverse events related to study drug were reported. Biomarker Assessments at Month 6 and Month 12 MRI Biomarkers (n=7): Brain Volume: At Month 6, there were similar declines in brain volume, as assessed by the MSA-atrophy index (MSA-AI)3 in all participants consistent with the nature of MSA.However, in the clinical responders, brain volume assessed by the MSA-AI was stable between Month 6 and Month 12. Iron content in the substantia nigra was stable over 12 months in the clinical responders.Myoinositol is an exploratory biomarker of glial cell pathology in MSA. Treatment with ATH434 led to smaller increases in myoinositol in clinical responders compared to participants who worsened. Fluid Biomarkers (n=5): Neurofilament Light Chain (NfL) is a marker of axonal injury in neurons and has been shown to correlate with disease severity in many neurological diseases. In the trial, clinical responders had stable spinal fluid NfL levels on average whereas those who declined clinically had increased spinal fluid NfL levels. Definitions and References 1 Unified MSA Rating Scale, Part I (historical review). Areas assessed include: Speech, swallowing, handwriting, cutting food/handling utensils, dressing, hygiene, walking, falling, orthostatic symptoms, urinary function, sexual function and bowel function. 2 Wenning et al. The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol 2013; 12: 264–74. 3 MSA Atrophy Index: This index measures the degree of atrophy relative to a normal population, with more negative values indicating greater atrophy About ATH434-202 Phase 2 Clinical Trial The ATH434-202 Phase 2 clinical trial is an open label study, entitled “A Biomarker Study of ATH434 in Participants with MSA.” The Biomarker trial enrolled 10 individuals with advanced MSA. ATH434-202 study participants will receive treatment with ATH434 for 12-months. The study will assess the effect of ATH434 treatment on neuroimaging and protein biomarkers to evaluate target engagement, in addition to clinical measures, safety, and pharmacokinetics. The selected biomarkers, including brain volume, iron and aggregating α-synuclein, are important contributors to MSA pathology and are appropriate targets to demonstrate drug activity. The primary objective of this study is to evaluate the impact of 12 months treatment with ATH434 on brain volume in a more advanced patient population than is being studied in Alterity’s randomized Phase 2 trial. Final, 12-month data from the ATH434-202 trial are expected in the first half of 2025. Additional information on the open label Phase 2 trial can be found at clinicaltrials.gov NCT05864365. About ATH434 Alterity’s lead candidate, ATH434, is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. ATH434 has been shown preclinically to reduce α-synuclein pathology and preserve neuronal function by restoring normal iron balance in the brain. As an iron chaperone, it has excellent potential to treat Parkinson’s disease as well as various Parkinsonian disorders such as Multiple System Atrophy (MSA). ATH434 successfully completed Phase 1 studies demonstrating the agent is well tolerated and achieved brain levels comparable to efficacious levels in animal models of MSA. ATH434 is currently being studied in two clinical trials: Study ATH434-201 is a randomized, double-blind, placebo-controlled Phase 2 clinical trial in patients with early-stage MSA and Study ATH434-202 is an open-label Phase 2 Biomarker trial in patients with more advanced MSA. ATH434 has been granted Orphan drug designation for the treatment of MSA by the U.S. FDA and the European Commission. About Multiple System Atrophy Multiple System Atrophy (MSA) is a rare, neurodegenerative disease characterized by failure of the autonomic nervous system and impaired movement. The symptoms reflect the progressive loss of function and death of different types of nerve cells in the brain and spinal cord. It is a rapidly progressive disease and causes profound disability. MSA is a Parkinsonian disorder characterized by a variable combination of slowed movement and/or rigidity, autonomic instability that affects involuntary functions such as blood pressure maintenance and bladder control, and impaired balance and/or coordination that predisposes to falls. A pathological hallmark of MSA is the accumulation of the protein α-synuclein within glia, the support cells of the central nervous system, and neuron loss in multiple brain regions. MSA affects at least 15,000 individuals in the U.S., and while some of the symptoms of MSA can be treated with medications, currently there are no drugs that are able to slow disease progression and there is no cure.1 1Multiple System Atrophy | National Institute of Neurological Disorders and Stroke (nih.gov) About Alterity Therapeutics Limited Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company’s lead asset, ATH434, has the potential to treat various Parkinsonian disorders and is currently being evaluated in two Phase 2 clinical trials in Multiple System Atrophy. Alterity also has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s web site at www.alteritytherapeutics.com. Authorisation & Additional informationThis announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited. Investor and Media Contacts: AustraliaHannah Howlettwe-aualteritytherapeutics@we-worldwide.com+61 450 648 064 U.S.Remy Bernardaremy.bernarda@iradvisory.com +1 (415) 203-6386 Forward Looking Statements This press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled “Risk Factors” in the Company’s filings with the SEC, including its most recent Annual Report on Form 20-F as well as reports on Form 6-K, including, but not limited to the following: statements relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, but not limited to, ATH434, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company’s drug components, including, but not limited to, ATH434, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to, ATH434, that could slow or prevent products coming to market, the uncertainty of obtaining patent protection for the Company's intellectual property or trade secrets, the uncertainty of successfully enforcing the Company’s patent rights and the uncertainty of the Company freedom to operate. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Clinical ResultPhase 2Phase 1Orphan Drug

22 Aug 2023

·www.globenewswire.com

Alterity Therapeutics Rare Disease Natural History Study to be Featured at the International Congress of Parkinson’s Disease and Movement Disorders

Presentations Highlight New Data on Diagnostic Accuracy and Novel Biomarkers of Disease Severity in Multiple System AtrophyMELBOURNE, Australia and SAN FRANCISCO, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that poster presentations from its bioMUSE natural history study of Multiple System Atrophy (MSA) will be delivered at the International Congress of Parkinson’s Disease and Movement Disorders taking place August 27 - 31, 2023 in Copenhagen, Denmark. Title:A multimodal approach for diagnosis of early Multiple System AtrophyPresenter:Daniel O. Claassen, M.D., M.S., Professor of Neurology, Vanderbilt University Medical CenterAbstract #:162Category:Parkinsonism, Atypical: MSADate: Monday, August 28, 2023Time: 13:00 - 15:00 local time Title:Preliminary evidence for evolution of myoinositol and N-acetylaspartate as biomarkers of disease severity in early-stage Multiple System AtrophyPresenter:Paula Trujillo Diaz, PhD, Research Assistant Professor, Department of Neurology, Vanderbilt University Medical CenterAbstract #:181Category:Parkinsonism, Atypical: MSADate:Monday, August 28, 2023Time:13:00 - 15:00 local time About bioMUSE Biomarkers of progression in Multiple System Atrophy (bioMUSE) is a natural history study that aims to track the progression of individuals with MSA, a parkinsonian disorder without approved therapy. The study is being conducted in collaboration with Vanderbilt University Medical Center in the U.S. under the direction of Daniel Claassen, M.D., M.S., Professor of Neurology and Principal Investigator. Natural history studies are important for characterizing disease progression in selected patient populations. The study has provided rich data for optimizing the design of Alterity’s randomized ATH434-201 Phase 2 clinical trial and enrolled approximately 20 individuals with clinically probable or clinically established MSA. BioMUSE continues to provide vital information on early stage MSA patients, informs the selection of biomarkers suitable to evaluate target engagement and preliminary efficacy, and delivers clinical data to characterize disease progression in a patient population that mirrors those currently enrolling in the Phase 2 clinical trial. About Multiple System Atrophy Multiple System Atrophy (MSA) is a rare, neurodegenerative disease characterized by failure of the autonomic nervous system and impaired movement. The symptoms reflect the progressive loss of function and death of different types of nerve cells in the brain and spinal cord. It is a rapidly progressive disease and causes profound disability. MSA is a Parkinsonian disorder characterized by a variable combination of slowed movement and/or rigidity, autonomic instability that affects involuntary functions such as blood pressure maintenance and bladder control, and impaired balance and/or coordination that predisposes to falls. A pathological hallmark of MSA is the accumulation of the protein α-synuclein within glia, the support cells of the central nervous system, and neuron loss in multiple brain regions. MSA affects approximately 15,000 individuals in the U.S., and while some of the symptoms of MSA can be treated with medications, currently there are no drugs that are able to slow disease progression and there is no cure.1 1Multiple System Atrophy | National Institute of Neurological Disorders and Stroke (nih.gov) About Alterity Therapeutics Limited Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company’s lead asset, ATH434, has the potential to treat various Parkinsonian disorders and is currently being evaluated in two Phase 2 clinical trials in Multiple System Atrophy. Alterity also has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s web site at www.alteritytherapeutics.com. Authorisation & Additional informationThis announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited. Investor and Media Contacts: AustraliaHannah Howlettwe-aualteritytherapeutics@we-worldwide.com+61 450 648 064 U.S.Remy Bernardaremy.bernarda@iradvisory.com +1 (415) 203-6386 Forward Looking Statements This press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled “Risk Factors” in the Company’s filings with the SEC, including its most recent Annual Report on Form 20-F as well as reports on Form 6-K, including, but not limited to the following: statements relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, but not limited to, ATH434, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company’s drug components, including, but not limited to, ATH434, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to, ATH434, that could slow or prevent products coming to market, the uncertainty of obtaining patent protection for the Company's intellectual property or trade secrets, the uncertainty of successfully enforcing the Company’s patent rights and the uncertainty of the Company freedom to operate. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Phase 2Clinical Result

100 Deals associated with Inositol

External Link

KEGG	Wiki	ATC	Drug Bank
D08079	Inositol	A11HA07	DB13178

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Arteriosclerosis	China	Yichang Humanwell Pharmaceuticals Co., Ltd.	01 Jan 1981
Fatty Liver	China	Yichang Humanwell Pharmaceuticals Co., Ltd.	01 Jan 1981
Hepatitis	China	Yichang Humanwell Pharmaceuticals Co., Ltd.	01 Jan 1981
Hyperlipidemias	China	Yichang Humanwell Pharmaceuticals Co., Ltd.	01 Jan 1981
Liver Cirrhosis	China	Yichang Humanwell Pharmaceuticals Co., Ltd.	01 Jan 1981

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04867252 (Pubmed \| Endocrine)	Phase 2	Polycystic Ovary Syndrome	88	Metformin and Pioglitazone	lrnaahaayk(wrgzhalhrx) = hewlhqppqr ertwivlmyd (rqfcxmrpxb )	Positive	28 Sep 2022
				Resveratrol and Myoinositol	lrnaahaayk(wrgzhalhrx) = hmmgycmzpz ertwivlmyd (rqfcxmrpxb )
NCT02397291 (CTgov)	Not Applicable	Pregnancy \| Fetal Growth Retardation	24	Placebo (Part 1: Measurements of Maternal and Fetal Concentrations)	hxllghlgic(qjwwpoxtef) = eqjbshxazr qwppnfjvao (xjonvgdzhj, yhkctonmbt - zrgwxrmyvg) View more	-	11 Nov 2021
				Myoinositol+Mannose (Part 2: Stable Isotope Studies)	hxllghlgic(qjwwpoxtef) = reipjowkur qwppnfjvao (xjonvgdzhj, ygjbybaddc - svcysruvqz) View more
NCT01030575 (INS-2, CTgov)	Phase 2	Bronchopulmonary Dysplasia \| Retinopathy of Prematurity	125	Inositol lower volume (Inositol Low Volume)	btrylpkets(luiwbsbxdd) = fisrltldtc rvbtyeexlk (xlixslettx, wdxabxawyn - pjmehqkkna) View more	-	12 Mar 2021
				Inositol (Inositol Mid-level Volume)	btrylpkets(luiwbsbxdd) = ytfzjclbyx rvbtyeexlk (xlixslettx, oupcbqgwwe - qtaiyxhkjg) View more
NCT01396486 (CTgov)	Phase 4	Mania \| Bipolar Disorder	69	Omega-3 (Omega-3/Placebo)	clzqapjedg(nvrnvfcqgd) = dsnyefvwge hlcpapgtub (thnundkmgj, fnrqxkgunl - hypakxuyhq) View more	-	21 Apr 2020
				Inositol (Placebo/Inositol)	clzqapjedg(nvrnvfcqgd) = evkrfntcsd hlcpapgtub (thnundkmgj, akayrjcrxe - lmujgjcfsw) View more
NCT01954082 (INS-3, CTgov)	Phase 3	Retinopathy of Prematurity	638	myo-Inositol 5% Injection (Myo-Inositol 5% Injection)	prtjhvhoce(agbxjanfks) = idaihagpoy ppmcxcsqrn (fslqnhxsdj, udootueylg - bgxacbfhaz) View more	-	26 Sep 2018
				Placebo (5% Glucose(Dextrose))	prtjhvhoce(agbxjanfks) = ckttlrdtib ppmcxcsqrn (fslqnhxsdj, imdrgxdkvi - wvhkzhqftj) View more
NCT01875445 (CTgov)	Phase 2	Trichotillomania	38	Placebo (Placebo)	jdbeistbyf(qagnuezqjb) = vhbnafqagl sodcvfheyl (obeoieatwl, xmgassngkt - mhzedcdudb) View more	-	19 May 2017
				Inositol (Inositol)	jdbeistbyf(qagnuezqjb) = zabtmwqksc sodcvfheyl (obeoieatwl, ltysyuysvu - uvsthtypgb) View more
NCT01111292 (CTgov)	Phase 1/2	Recurrent Colon Cancer \| Rectal Cancer \| Crohn Disease \| Dysplasia \| Colitis, Ulcerative	5	Inositol (Arm I (Inositol))	tqgulrzpyy(nbzlwzdgiw) = kxxafodphg swaivbadgf (athhywudoc, pufjwvxywx - pzaxixtjri) View more	-	12 Jul 2016
				Placebo (Arm II (Placebo))	tqgulrzpyy(nbzlwzdgiw) = cuzvqmoujs swaivbadgf (athhywudoc, fdjgwsedbf - nzrsoelevs) View more
NCT00783705 (CTgov)	Phase 2	Non-Small Cell Lung Cancer \| Bronchial Diseases	85	inositol (Arm A (Myo-inositol))	(jmlurlvpyz) = aekjifxrnp eyncutwsur (tnnwrqxzpd, rxbzgcjhvu - hprigscvmr) View more	-	25 Aug 2015
				Placebo (Arm B (Placebo))	(jmlurlvpyz) = jmmslamnrz eyncutwsur (tnnwrqxzpd, koyeuhokuu - bzuldmbngp) View more
NCT00012558 (STEP-BD, Pubmed \| Am J Psychiatry)	Not Applicable	Depressive Disorder, Treatment-Resistant	66	Lamotrigine	nbzytedecy(pbgmbewpgn) = nvyjkjhrdc lkrdahqjxu (atoeennhih )	Positive	01 Feb 2006
				Inositol	nbzytedecy(pbgmbewpgn) = vqqpxyqnur lkrdahqjxu (atoeennhih )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis